

CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

28th of April 2023

BARCELONA

Virtual and in-person







1ST WORKSHOP CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

April 28th 2023



DIRECTORS:

Dr. Joan Genescà, Clinical Director of Digestive Diseases and Chief of Liver Unit, Vall d'Hebron University Hospital; Professor of Medicine, Universitat Autònoma de Barcelona; CIBERehd, Institute of Health Carlos III.

Dr. Juan M Pericàs, Consultant at Liver Unit, Vall d'Hebron University Hospital; CIBERehd Institute of Health Carlos III.

OBJECTIVES:

- 1. Overview of the current situation and regulatory requirements in NASH clinical trials
- 2. Review of endpoints for clinical trials in NASH patients with cirrhosis
- 3. Alternative options for the design of clinical trials in NASH patients with cirrhosis

VENUE:

Conference room – Floor 1 Pabellón docente Vall d'Hebron Barcelona Hospital Campus 119-129 Vall d'Hebron Avenue 08035 Barcelona, Spain



ACCREDITATION:

Accreditation requested by the **European Accreditation Council for Continuing Medical Education** (EACCME – an Institution of the UEMS) to provide continuing medical education for physicians. A certificate of assistance will be awarded to participants attending at least **80%** of the session.

REGISTRATION:

In-person registration fee:250,00€Virtual registration fee:100,00€On-demand fee:50,00€

Lunch and coffee breaks are included.

Registrations must be made through the following website: https://aula.vallhebron.com/ (future courses section).

Special dietary requirements must be notified to Technical Secretary during the registration process (inscripcionsaulavh@vhebron.net).

TECHNICAL SECRETARY:

Aula Vall d'Hebron -

inscripcionsaulavh@vhebron.net - +34 693785436










1ST WORKSHOP CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

April 28th 2023



SPEAKERS AND MODERATORS

AGUSTIN ALBILLOS

Professor of Medicine, University of Alcalá, Madrid Head, Department of Gastroenterology and Hepatology, Hospital Ramón y Cajal, Madrid (Spain)

QUENTIN ANSTEE

Professor of Experimental Hepatology, Newcastle University, Newcastle (United Kingdom)

SALVADOR AUGUSTIN

Senior Clinical Program Lead - NASH Boehringer Ingelheim International GmbH (Germany)

RAFAEL BAÑARES

Professor of Medicine, Complutense University of Madrid
Chief Digestive Medicine Department, Gregorio Marañon General University
Hospital
Scientific Director of Liver and Digestive Diseases area. CIBERISCIII

RON BASUROY – NOVO NORDISK

Medical Director - NASH Novo Nordisk A/S

RAMÓN BATALLER

Chief Liver Unit, Hospital Clinic, Barcelona (Spain)

ANNALISA BERZIGOTTI

Head of Hepatology a.i. Clinic Director Department of Visceral Surgery and Medicine Inselspital, Bern University Hospital (Switzerland)

JAUME BOSCH

Professor of Medicine, Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital (Switzerland)

LISA BOYETTE

Senior Director of Clinical Development Gilead Sciences, Inc

JOSE LUIS CALLEJA

Professor of Medicine, Universidad Autónoma Madrid Chief of Gastroenterology and Hepatology units, Puerta de Hierro University Hospital, Madrid (Spain)

ANDREEA CIUDIN

Endocrinology and Nutrition Department, Morbid Obesity Unit Coordinator, Vall d'Hebron University Hospital

Associated Professor of Human Physiology, Autonomous University of

Member of the Directory Board of the Spanish Society of Obesity, SEEDO Investigator of CIBERdem, Institute of Health Carlos III (Spain)

CLAUDIA DE OLIVEIRA

Clinical Development Lead, Liver Fibrosis and Cendakimab Global Drug Development | Research & Development Bristol Myers Squibb

SVEN FRANCQUE

Chairman – Division of Gastroenterology and Hepatology, Antwerp University Hospital

Senior Full Professor of Medicine – Laboratory of Experimental Medicine and Paediatrics (Faculty of Medicine and Health Sciences), University of Antwerp (Belgium)

JOAN GENESCÀ

Clinical Director of Digestive Diseases and Chief of Liver Unit, Vall d'Hebron University Hospital

Head of the Advanced Chronic Liver Diseases Research Group, CIBERehd Institute of Health Carlos III

Professor of Medicine, Autonomous University of Barcelona (Spain)

JUAN GONZÁLEZ-ABRALDES

Professor of Medicine
Director, Liver Unit
Division of Gastroenterology, University of Alberta
AHS Hepatology Lead, Edmonton Zone (Canada)

VIRGINIA HERNÁNDEZ-GEA

Hepatic hemodynamic Unit, Liver Unit, Hospital Clinic – IDIBAPS, Barcelona (Spain)

Investigator of CIBERehd, Institute of Health Carlos III Secretary of VALDIG EASL Scientific committee & Governing Board ERN Rare-Liver managing team

JUAN M PERICÀS

Consultant at Liver Unit, Vall d'Hebron University Hospital, Barcelona Investigator of CIBERehd Institute of Health Carlos III (Spain)

MÒNICA PONS

Consultant at Liver Unit, Vall d'Hebron University Hospital, Barcelona (Spain)

THOMAS REIBERGER

Division of Gastroenterology and Hepatology Department of Medicine III, Medical University of Vienna Head of Liver Cirrhosis Clinic Director of Christian Doppler Lab for Portal Hypertension and Liver Fibrosis

Director of Christian Doppler Lab for Portal Hypertension and Liver Fibrosis Adjunct PI at CeMM and at LBI for Rare and Undiagnosed Diseases (LBI-RUD), Vienna (Austria)

IAN ROWE

Associate Professor, University of Leeds Institute for Medical Research Honorary

Consultant Hepatologist at the Leeds Liver Unit, Leeds (United Kingdom)

PETER RYDQVIST

Medical Director – Europe Madrigal Pharmaceuticals

ELMER SCHABEL

Federal Institute for Drugs and Medical Devices, Bonn (Germany)

FRANK TACKE

Department Head and Professor of Medicine Charité - Universitätsmedizin Berlin Department of Hepatology and Gastroenterology Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM) (Germany)

EMMANUEL TSOCHATZIS

Professor of Hepatology UCL Institute for Liver and Digestive Health, Royal Free Hospital (United Kingdom)

VÍCTOR VARGAS

Senior consultant at Liver Unit, Vall d'Hebron University Hospital Professor of Medicine, Autonomous University of Barcelona (Spain)










1ST WORKSHOP CLINICAL TRIALS IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS

April 28th 2023



9:00 - 9:15h	Welcome: Dr. Jose Luís Calleja and Dr. Joan Genescà
9:20 - 11:00h	SESSION I. Current landscape and regulatory issues (1h 40min) Moderators: V. Vargas and S. Augustin 1. Current situation of clinical trials in NASH (20 min) – F. Tacke 2. Clinical trials in NASH cirrhosis: challenges (20 min) – S. Augustin 3. Regulatory aspects: EMA position (20 min) – E. Schabel 4. Regulatory aspects: FDA position (20 min) – P. Rydqvist Discussion (20 min)
11:00 - 11:20h	Coffee break (20 min)
11:20 - 13:00h	SESSION II. Weight loss and bariatric surgery in NASH cirrhosis (1h 40min) Moderators: R. Bañares and R. Basuroy 1. Effects of weight loss in cirrhotic NASH patients (20 min) – A. Berzigotti 2. Drugs for obesity in NASH patients (20 min) – A. Ciudin 3. Bariatric surgery in NASH: overview of results (20 min) – S. Francque 4. How to select NASH cirrhotic patients for bariatric surgery (20 min) – T. Reiberger Discussion (20 min)
13:00 - 14:00h	Lunch (60 min)
14:00 - 15:40h	SESSION III. Endpoints in NASH cirrhosis clinical trials (1h 40min) Moderators: A. Albillos and C. Oliveira 1. Liver Biopsy (20 min) – JM. Pericàs 2. Surrogate endpoints: HVPG (20 min) – V. Hernández-Gea 3. Other non-invasive endpoints (20 min) – Q. Anstee 4. Clinical endpoints (20 min) – E. Tsochatzis Discussion (20 min)
15:40 - 16:00h	Coffee break (20 min)
16:00 - 17:30h	SESSION IV. Alternatives in design for NASH cirrhosis clinical trials (1h 30min) Moderators: J. Bosch and L. Boyette 1. Prognostic models in NASH cirrhosis (20 min) – <i>M. Pons</i> 2. Ordinal outcomes for NASH cirrhosis clinical trials (20 min) – <i>JG. Abraldes</i> 3. How NASH cirrhosis clinical trials might be in the future? (20 min) – <i>I. Rowe</i> Discussion all panelists (30 min)



17:30 - 17:45h


Greetings & concluding remarks: Dr. Ramón Bataller and Dr. Joan Genescà







1ST WORKSHOP CLINICAL TRIALS IN NASH **PATIENTS WITH COMPENSATED CIRRHOSIS** April 28th 2023



SPONSORED BY

PLATINUM SPONSORSHIP

SAPPHIRE SPONSORSHIP

GOLDEN SPONSORSHIP

SILVER SPONSORSHIP

BRONZE SPONSORSHIP

